Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

26 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Specific active immunotherapy with a VEGF vaccine in patients with advanced solid tumors. results of the CENTAURO antigen dose escalation phase I clinical trial.
Gavilondo JV, Hernández-Bernal F, Ayala-Ávila M, de la Torre AV, de la Torre J, Morera-Díaz Y, Bequet-Romero M, Sánchez J, Valenzuela CM, Martín Y, Selman-Housein KH, Garabito A, Lazo OC; CENTAURO Group of Investigators. Gavilondo JV, et al. Vaccine. 2014 Apr 17;32(19):2241-50. doi: 10.1016/j.vaccine.2013.11.102. Epub 2014 Feb 11. Vaccine. 2014. PMID: 24530151 Clinical Trial.
Indirect and competitive enzyme-linked immunosorbent assays for monitoring the humoral response against human VEGF.
Sánchez Ramírez J, Morera Díaz Y, Musacchio Lasa A, Bequet-Romero M, Muñoz Pozo Y, Pérez Sánchez L, Hernández-Bernal F, Mendoza Fuentes O, Selman-Housein KH, Gavilondo Cowley JV, Ayala Avila M. Sánchez Ramírez J, et al. J Immunoassay Immunochem. 2016;37(6):636-58. doi: 10.1080/15321819.2016.1184164. J Immunoassay Immunochem. 2016. PMID: 27143151
Specific humoral and cellular immune responses in cancer patients undergoing chronic immunization with a VEGF-based therapeutic vaccine.
Morera Y, Sánchez J, Bequet-Romero M, Selman-Housein KH, de la Torre A, Hernández-Bernal F, Martín Y, Garabito A, Piñero J, Bermúdez C, de la Torre J, Ayala M, Gavilondo JV. Morera Y, et al. Vaccine. 2017 Jun 16;35(28):3582-3590. doi: 10.1016/j.vaccine.2017.05.020. Epub 2017 May 20. Vaccine. 2017. PMID: 28536029 Clinical Trial.
Characteristics of the specific humoral response in patients with advanced solid tumors after active immunotherapy with a VEGF vaccine, at different antigen doses and using two distinct adjuvants.
Sánchez Ramírez J, Morera Díaz Y, Bequet-Romero M, Hernández-Bernal F, Selman-Housein Bernal KH, de la Torre Santos A, Santiesteban Álvarez ER, Martín Bauta Y, Bermúdez Badell CH, de la Torre Pupo J, Gavilondo JV; CENTAURO-2 Team of Investigators; Ayala Avila M. Sánchez Ramírez J, et al. BMC Immunol. 2017 Jul 26;18(1):39. doi: 10.1186/s12865-017-0222-z. BMC Immunol. 2017. PMID: 28747172 Free PMC article. Clinical Trial.
Evaluation of methodologies to determine the effect of specific active immunotherapy on VEGF levels in phase I clinical trial patients with advanced solid tumors.
Sánchez Ramírez J, Bequet-Romero M, Morera Díaz Y, Hernández-Bernal F, de la Torre Santos A, Selman-Housein Bernal KH, Martín Bauta Y, Bermúdez Badell CH, Limonta Fernández M, Ayala Avila M. Sánchez Ramírez J, et al. Among authors: hernandez bernal f. Heliyon. 2018 Nov 2;4(11):e00906. doi: 10.1016/j.heliyon.2018.e00906. eCollection 2018 Nov. Heliyon. 2018. PMID: 30426104 Free PMC article.
Specific humoral response in cancer patients treated with a VEGF-specific active immunotherapy procedure within a compassionate use program.
Sánchez Ramírez J, Morera Díaz Y, Bequet-Romero M, Hernández-Bernal F, Martín Bauta Y, Selman-Housein Bernal KH, de la Torre Santos AV, Pérez de la Iglesia M, Trimiño Lorenzo L; Team of Investigators of Compassionate use Program; Ayala Avila M. Sánchez Ramírez J, et al. Among authors: hernandez bernal f. BMC Immunol. 2020 Mar 14;21(1):12. doi: 10.1186/s12865-020-0338-4. BMC Immunol. 2020. PMID: 32171254 Free PMC article.
Safety, tolerability, and immunogenicity of a SARS-CoV-2 recombinant spike RBD protein vaccine: A randomised, double-blind, placebo-controlled, phase 1-2 clinical trial (ABDALA Study).
Hernández-Bernal F, Ricardo-Cobas MC, Martín-Bauta Y, Navarro-Rodríguez Z, Piñera-Martínez M, Quintana-Guerra J, Urrutia-Pérez K, Urrutia-Pérez K, Chávez-Chong CO, Azor-Hernández JL, Rodríguez-Reinoso JL, Lobaina-Lambert L, Colina-Ávila E, Bizet-Almeida J, Rodríguez-Nuviola J, Del Valle-Piñera S, Ramírez-Domínguez M, Tablada-Ferreiro E, Alonso-Valdés M, Lemos-Pérez G, Guillén-Nieto GE, Palenzuela-Díaz A, Noa-Romero E, Limonta-Fernández M, Fernández-Ávila JM, Ali-Mros NA, Del Toro-Lahera L, Remedios-Reyes R, Ayala-Ávila M, Muzio-González VL. Hernández-Bernal F, et al. EClinicalMedicine. 2022 Apr;46:101383. doi: 10.1016/j.eclinm.2022.101383. Epub 2022 Apr 9. EClinicalMedicine. 2022. PMID: 35434578 Free PMC article.
Cuban Abdala vaccine: Effectiveness in preventing severe disease and death from COVID-19 in Havana, Cuba; A cohort study.
Más-Bermejo PI, Dickinson-Meneses FO, Almenares-Rodríguez K, Sánchez-Valdés L, Guinovart-Díaz R, Vidal-Ledo M, Galbán-García E, Olivera-Nodarse Y, Morgado-Vega I, Dueñas-Carrera S, Pujol M, Hernández-Bernal F, Limonta-Fernández M, Guillén-Nieto G, Muzio-González VL, Ayala-Ávila M. Más-Bermejo PI, et al. Among authors: hernandez bernal f. Lancet Reg Health Am. 2022 Dec;16:100366. doi: 10.1016/j.lana.2022.100366. Epub 2022 Sep 24. Lancet Reg Health Am. 2022. PMID: 36185968 Free PMC article.
26 results